3 Dividend Stocks to Double Up on Right Now

Key Points

• AbbVie is a Dividend King with an attractive valuation.

• Enbridge is a resilient energy stock with a high dividend yield.

• Realty Income pays a juicy monthly dividend and has strong growth prospects.

• 10 stocks we like better than AbbVie ›

When you're highly confident about your cards in the game of blackjack, you double down. This means that you double your initial bet in exchange for receiving only one additional card. If you win, you make even more money.

This same concept can apply to investing in dividend stocks, although I prefer the term "double up" instead of "double down." The key thing, though, is that you have to feel really good about the stocks' prospects to do it. With that in mind, here are three dividend stocks to double up on right now, in my opinion.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

1. AbbVie

Let's start with a member of the dividend royalty. AbbVie (NYSE: ABBV) is a Dividend King with 53 consecutive years of dividend increases. What's even more impressive is how much this big drugmaker has grown its dividend. Since spinning off from Abbott Labs (NYSE: ABT) in 2013, AbbVie has increased its dividend payout by a remarkable 310%. Its forward dividend yield currently stands at a healthy 3.1%.

AbbVie has been a big winner so far in 2025, handily outperforming the broader market. The primary reason for the stock's nice gains is that the company's sales and adjusted profits are growing solidly, thanks in large part to autoimmune disease drugs Rinvoq and Skyrizi.

The success of those two drugs reflects a lower risk level for AbbVie following the 2023 loss of U.S. exclusivity for the company's former top-selling drug, Humira. AbbVie has navigated that patent cliff exceptionally well and no longer depends on Humira to drive its growth.

Another reason I view AbbVie as a great dividend stock to buy right now is its valuation. The stock trades at a relatively low forward earnings multiple of 15. Its price-to-earnings-to-growth (PEG) ratio, which is based on analysts' five-year earnings growth projections, is a super-low 0.38. Few stocks offer the combination of attractive income, growth, and valuation that AbbVie does.

2. Enbridge

If you're feeling a little jittery about the stock market these days, you're not alone. Some dividend stocks, though, are highly resilient. I think Enbridge (NYSE: ENB) is in that group.

Enbridge is probably best known for its extensive pipeline network, which spans over 90,000 miles, including the company's DCP Midstream joint venture with Phillips 66 (NYSE: PSX). Those pipelines transport roughly 30% of the crude oil produced in North America and around 20% of the natural gas consumed in the U.S. Enbridge is also the largest natural gas utility in North America, based on volume.

These businesses give the company tremendous stability. During the financial crisis of 2007 to 2008, the oil price collapse in 2015, and the COVID-19 pandemic of 2020 and 2021, Enbridge delivered consistent adjusted earnings and distributable cash flow.

Unsurprisingly, Enbridge has an impressive track record of 30 consecutive years of dividend increases. Income investors should also love its forward dividend yield of 5.65%.

3. Realty Income

Realty Income (NYSE: O) is similar to Enbridge on the dividend front. The real estate investment trust (REIT) has also increased its dividend for 30 consecutive years. Its forward dividend yield of 5.57% is also close to Enbridge's yield. Perhaps the main difference with Realty Income's dividend is that it's paid monthly rather than quarterly.

Another commonality with Enbridge is Realty Income's stability. The company's portfolio is highly diversified, with 1,630 clients from 91 different industries. Most of Realty Income's properties are in the U.S., although the company also owns properties in Europe and the United Kingdom.

None of Realty Income's clients generate more than 3.5% of total annualized contractual rent. The REIT's top five clients make up only 15% of total rent. While nearly 80% of Realty Income's properties are leased to retailers, most of them operate in nondiscretionary, low-price-point, and/or service-oriented retail markets that help lower the company's risk.

Realty Income's total addressable market in the U.S. is $5.5 trillion. Its European opportunity is even bigger at $8.5 trillion. Realty Income also faces only one major competitor in the European market. These growth prospects, combined with the REIT's strong dividend and stability, make this dividend stock a great pick to double up on right now.

Should you invest $1,000 in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $670,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,023,752!*

Now, it’s worth noting Stock Advisor’s total average return is 1,052% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 25, 2025

Keith Speights has positions in AbbVie, Enbridge, and Realty Income. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, Enbridge, and Realty Income. The Motley Fool recommends Phillips 66. The Motley Fool has a disclosure policy.